DJIA 17,804.80 26.65 0.15%
NASDAQ 4,765.38 16.98 0.36%
S&P 500 2,070.65 9.42 0.46%
market minute promo

70.23 2.14 (3.14%)

Quote as of

company name or ticker

Recent Quotes

GWPH $70.23 3.14%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $68.80
Previous Close $68.09
Daily Range $67.21 - $71.00
52-Week Range $31.05 - $111.46
Market Cap $1.4B
P/E Ratio -113.48
Dividend (Yield) $0.00 (0.0%)
Volume 682,196
Average Daily Volume 368,872
Current FY EPS -$4.64



GW Pharmaceuticals Plc (ADR) (GWPH) Description

GW Pharmaceuticals Plc - American Depositary Shares Website:

News & Commentary

Could the Next Generation of Diabetes Treatments Be Found in This Illegal Drug?

Diabetes affects more than 29 million Americans and can lead to a number of serious complications. However, this currently illegal drug could provide a new pathway for diabetics to achieve better glycemic balance.

A New Study on Diabetes Reveals Potentially Frightening News

Diabetes affects 29.1 million people in the United States, and is a dangerous long-term disease in its own right. This latest study, however, could add another aspect for diabetics to worry about.

Twitter's Favorite Biotech and Pharma Stocks

Consensus? We don't need no stinking consensus!

How to Buy Great Healthcare Stocks

What makes a good healthcare stock? In this episode, we discuss what investors should look for when evaluating healthcare stocks, including one company to watch, and one to avoid.

Covidien Loses $176M Award in Patent Case Against JNJ Unit - Analyst Blog

Why GW Pharmaceuticals Is Currently The Only Game In Town For A Cannabis Play

American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Sto

American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks

Could Marijuana Be the Answer to Fighting This Deadly Disease?

A recent study showed that cannabinoids could be an effective treatment in slowing the progression of a deadly disease which is expected to see diagnoses grow by 176% between now and 2050.

Should Big Pharma Buy Into the Medical Marijuana Industry?

Two Motley Fool analysts share there competing views on whether or not big drugmakers should jump into the medical marijuana market.

Baxter: Strong Sell on Prevailing Headwinds, Estimate Revision - Analyst Blog

See More GWPH News...